

May 12, 2022



Aptose to Hold KOL Event and Corporate Update Thursday, June 2nd

Clinical Updates for HM43239 and Luxeptinib

*Poster Presentation for HM43239 is Scheduled for June 10th at
EHA2022 Hybrid Congress*

SAN DIEGO and TORONTO, May 12, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the company management team, along with guest key opinion leaders (KOLs), will provide an update for the investment community on Thursday, June 2nd at 4:30 PM. The event will include an up-to-date review of clinical data available for Aptose's two investigational products under development for hematologic malignancies: HM43239, an oral, myeloid kinome inhibitor in an international Phase 1/2 trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib, an oral, dual lymphoid and myeloid kinome inhibitor in a Phase 1 a/b trial in patients with relapsed or refractory B-cell malignancies, and in a separate Phase 1 a/b trial in patients with relapsed or refractory AML or high risk myelodysplastic syndrome (MDS).

Aptose Corporate Update Details

Date & Time: Thursday, June 2nd, 4:30 PM ET

Participant Webcast Link: [here](#)

The slides will be available on Aptose's website [here](#) and a recording of the presentation will be archived shortly after the conclusion of the event.

Separately, preclinical data for HM43239 also will be presented in a poster at the [EHA2022 Hybrid Congress](#), to be held in Vienna, Austria June 9 - 17, 2022 and virtually. The accepted abstract is being published today, Thursday, May 12th at 16:00 CEST / 10:00 AM ET.

Poster Presentation Details

Title:	Myeloid Kinome Inhibitor HM43239 Overcomes Acquired Resistance in Acute Myeloid Leukemia Models
Session Title:	Poster session
Session Date/Time:	Friday, June 10, 2022, 16:30 - 17:45 CEST
Final Abstract Code:	P461
Presenting Author:	Rafael Bejar

The poster also will be available on the presentations page of Aptose website [here](#).

About Aptose

Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage investigational products under development for hematologic malignancies: HM43239, an oral, myeloid kinase inhibitor in an international Phase 1/2 trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxetinib, an oral, dual lymphoid and myeloid kinase inhibitor in a Phase 1 a/b trial in patients with relapsed or refractory B-cell malignancies who have failed or are intolerant to standard therapies, and in a separate Phase 1 a/b trial in patients with relapsed or refractory AML or high risk myelodysplastic syndrome (MDS). For more information, please visit www.aptose.com.

For further information, please contact:

Aptose Biosciences Inc.

Susan Pietropaolo
Corporate Communications & Investor Relations
201-923-2049
spietropaolo@aptose.com

LifeSci Advisors, LLC

Dan Ferry, Managing Director
617-535-7746
Daniel@LifeSciAdvisors.com



Source: Aptose Biosciences, Inc.